Abstract

STUDY OF ? LACTAM RESISTANCES IN MRSA FOR DEVELOPMENT OF VACCINE

*Nagesh N. Patil, Abhishek Salunkhe, Abhijeet Nimbalkar, Aditya Patil, Hirachand Khade

ABSTRACT

The Staphylococcus aureus is evolutionary develops resistance to any antibiotics. The widespread use develops resistance to β lactams in Staphylococcus aureus. It reduces susceptibility towards penicillin, methicillin and vancomycin antibiotics. MRSA is a major cause of soft tissue and skin infection. The high growth rate, rapidly spread with in community are characteristics of community-MRSA. The mecA gene of SSCmec cassette is developing resistance against antibiotics. The mecA gene encodes the penicillin binding protein (PBP2a) with low affinity for β-lactam. The type IV SCCmec chromosome cassette produces Panton Valentine leukocidin (PVL) toxin, which is responsible for more virulence. The control of MRSA is very difficult due to changes in study data from publications to publications, change in screening, populations, protocols, healthcare practices and infection control efforts. Now to reduce the drug resistance this review suggests that use non β lactam antibiotics to cure MRSA. In 2010, FDA approved linezolid (Zyvox – Pfizer) for treatment of MRSA. The several new approaches are under investigation to replace antimicrobial therapy. Antimicrobial peptides, vaccines are most areas of interest to develop new therapy. Researcher use glycolipids, mutated protein A as an antigen for vaccine development but all cases are unsuccessful. Target vaccine should be against the Panton Valentine leukocidin (PVL). Interleukin 17 secreted by the TH 17 cell are the key factor for development of vaccine for MRSA.

Keywords: ? lactam, CA-MRSA, SSCmec, PVL, linezolid,Interleukin 17.